Discover our resources to learn about the pathways and treatments in cancer biology. From the tumor microenvironment to new targets for immunotherapies, you can explore our educational resources and find our reagents to empower your cancer research.


Webinar: Spatial Characterization of the Lung Tumor Microenvironment in Response to KRAS G12C Inhibition


The first inhibitor targeting KRAS G12C was recently approved for the treatment of locally advanced or metastatic NSCLC. In this webinar, Dr. Febe van Maldegem of The Francis Crick Institute will discuss the group's development of an Imaging Mass Cytometry workflow to phenotypically and spatially characterize the tumor microenvironment in mouse tissues. Using this approach, they have shown how targeted KRAS G12C inhibition leads to a dramatic remodeling of the lung tumor microenvironment.



A Deeper View of Cancer with Single-Cell Multiomics


See how researchers are using our TotalSeq™ reagents to accelerate cancer research by determining mechanisms of regulation of immune checkpoint inhibitors and creating an atlas of human tumors.


Read the blog>

STING Activators as
Cancer Therapeutics


Read about the STING pathway and how researchers are promoting immune surveillance, and testing novel cancer therapies.


Read now>


Cancer Immunotherapy
and Immune Checkpoints


Understand how our biofunctional antibodies target immune checkpoints and aid in immunotherapy research.


Read now>


Advancements in Using iNKTs for Cancer Immunotherapy


Learn about promising research finding new ways to harness the power of invariant NKT cells to fight cancer.


Read now>



Our Cancer Immunoediting poster describes the mechanisms by which the immune system responds to cancer and can be broadly split into three phases: elimination, equilibrium, and escape.


During the elimination phase, the immune system surveils and eliminates tumor cells through the production of inflammatory cytokines, recognition of tumor antigens by dendritic cells, or activation of natural killer cells.


Equilibrium describes a phase of cancer persistence in which there is a selection for tumor cells that were not eliminated. Tumor cells are selected through immune cell exhaustion or inhibition, genetic and epigenetic changes, or resistance to immune detection.


Escape occurs when tumors cells have avoided immune detection and are able to grow and expand.


Request a physical copy>


Login / Register
Remember me
Forgot your password? Reset password?
Create an Account